Browse All
Displaying 1 - 5 of 7
Author:Kieseier, Bernd Tisserand, Sarah Ramseier, Pamela Uffelmann, Tatjana Locatelli, Giuseppe Cenni, Bruno Nuesslein-Hildesheim, Barbara Bigaud, Marc
Session Name:S17: Multiple Sclerosis: Immunology/Basic Sciences
Topic:Multiple Sclerosis
Program Number:S17.008
Author Institution:Novartis Pharma AG, Basel, Switzerland
Author:Boer, Ibolya Cree, Bruce Wiendl, Heinz Cross, Anne Delgado, Sylvia Habek, Mario Khachanova, Natalia Ward, Brian Totolyan, Natalia Mancione, Linda Sullivan, Roseanne Zielman, Ronald Hu, Xixi Das Gupta, Ayan Montalban, Xavier Winthrop, Kevin
Session Name:P1: Multiple Sclerosis: Clinical Practice and Decision Making 1
Program Number:P1.010
Author Institution:Novartis Pharma AG, Basel, Switzerland UCSF Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA Department of Neurology with Institute of Translational Neurology, University of Münster, Muenster, Germany Washington University School of Medicine, Saint Louis, MO University of Miami Miller School of Medicine, Miami, FL University Hospital Center Zagreb, University of Zagreb, School of Medicine, Zagreb, Croatia Pirogov Russian National Research Medical University, Moscow, Russian Federation Infectious Diseases Division, Research Institute of the McGill University Health Centre, Montreal, QC, Canada First Saint Petersburg State Medical University, St Petersburg , Russian Federation Novartis Pharmaceuticals Corporation, East Hanover, NJ Novartis Pharma B.V, Amsterdam, Netherlands Novartis Healthcare Private Limited, Hyderabad, India Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona, Spain School of Public Health at Oregon Health & Science University, Portland, OR
Author:Kieseier, Bernd Montalban, Xavier Williams, Mitzi Airas, Laura Saini, Sarbjit Hide, Michihiro Sussman, Gordon Nakahara, Jin Bermel, Robert Doerner, Thomas Loop, Brett DeLasHeras, Virginia Willi, Roman Haemmerle, Sibylle Zharkov, Artem Barbier, Nathalie Azmon, Amin Siegel, Richard Cenni, Bruno Wiendl, Heinz Maurer, Marcus Gimenez-Arnau, Ana Chitnis, Tanuja
Session Name:P8: Multiple Sclerosis: Non-MS CNS Neuroinflammatory Diseases and Progressive MS and Remyelination/Neuroprotection
Program Number:P8.015
Author Institution:Novartis Pharma AG, Basel, Switzerland Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona, Spain Joi Life Wellness Group, Atlanta, GA Turku University Hospital and University of Turku, Turku, Finland Johns Hopkins Asthma and Allergy Center, Baltimore, MD Hiroshima Citizens Hospital, Minami-ku, Japan University of Toronto, Toronto, ON, Canada Department of Neurology, Keio University School of Medicine, Tokyo, Japan Mellen Center for MS, Cleveland Clinic, Cleveland, OH Department of Rheumatology and Clinical Immunology, Charite – Universitätsmedizin Berlin, Berlin, Germany Novartis Pharmaceutical Corporation, Cambridge, MA Novartis Institutes for Biomedical Research, Basel, Switzerland Department of Neurology with Institute of Translational Neurology, University of Münster, Muenster, Germany Urticaria Center of Reference and Excellence, Institute of Allergology, Charité – Universitätsmedizin Berlin, Berlin, Germany Department of Dermatology, Hospital del Mar – IMIM, Universitat Pompeu Fabra, Barcelona, Spain Department of Neurology, Brigham and Women's Hospital, Boston, MA
Author:Freeman, Jason Delgado, Silvia Alvarez, Enrique Thouvenot, Eric Okai, Annette Bhatt, Alit Wei, Wenjia Ziemssen, Tjalf
Session Name:P9: Multiple Sclerosis: Clinical Trials and Therapeutics (including Safety) 2
Program Number:P9.006
Author Institution:Novartis Pharmaceuticals, USCDMA , East Hanover , NJ University of Miami Miller School of Medicine, Miami, FL University of Colorado School of Medicine, Aurora, CO CHU Nîmes, Univ Montpellier, Nîmes, France North Texas Institute of Neurology and Headache, Plano, TX Novartis Healthcare Pvt. Ltd., Hyderabad, India Novartis Pharma AG, Basel, Switzerland University Clinic Carl-Gustav Carus, Dresden, Germany
Author:Bar-Or, Amit Wiendl, Heinz De Seze, Jerome Correale, Jorge Cross, Anne Derfuss, Tobias Selmaj, Krzysztof Winthrop, Kevin Giacomini, Paul Sacca, Francesco Hu, Xixi Sullivan, Roseanne Jehl, Valentine Boer, Ibolya Bhatt, Alit Hauser, Stephen
Program Number:P9.007
Author Institution:Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA University of Muenster, Muenster, Germany University Hospital of Strasbourg, Strasbourg, France Institute for Neurological Research Dr. Raul Carrea, Buenos Aires, Argentina Washington University School of Medicine, Clayton, MO Neurology Clinic and Policlinic and Research Center for Clinical Neuroimmunology and Neuroscience, Departments of Medicine and Biomedicine, University Hospital and University of Basel, Basel, Switzerland Center for Neurology, Lodz, Lodz, Poland Public Health and Preventive Medicine, Division of Infectious Diseases, Oregon Health and Sciences University, Portland, OR Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, QC, Canada NSRO Department, University “Federico II” of Naples, Naples, Italy Novartis Pharmaceuticals Corporation, East Hanover, NJ Novartis Pharma AG, Basel, Switzerland Novartis Healthcare Pvt. Ltd., Hyderabad, India UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA
